Khagi, S., Carrillo, J. A., Park, D. J., Lewis, C., Drusbosky, L., Bhar, P., Hong, L., Sender, L., Reddy, S. B., Kesari, S., Soon-Shiong, P. (2026). Response in first-in-human chemotherapy-free combination immunotherapy targeting lymphopenia in recurrent glioblastoma multiform (GBM): Nogapendekin alfa inbakicept (NAI) and PD-L1 t-haNK plus bevacizumab (BEV).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e14079